Our results regarding the body weight and fatty liver score increases after doxepin treatment in obese mice are potentially attributable to the reduction in the serum levels of FGF-21, which attenuated protection against NAFLD (including nonalcoholic fatty liver and nonalcoholic steatohepatitis) [40,52]. The gene discussed is FGF21; the disease is non-alcoholic fatty liver.